Iterum Therapeutics(ITRMF)
$0.030.00 (0.00%)
ITRMF
Iterum Therapeutics financials statements
$0.03
At close:0.00 (0.00%)
Want to see ITRMF full AI Analyst Report?
Iterum Therapeutics (ITRMF) Ratios
951 Followers
Iterum Therapeutics Ratios
ITRMF's free cash flow for Q3 2025 was $-7.86M. For the 2025 fiscal year, ITRMF's free cash flow was decreased by $-12.57K and operating cash flow was $-7.85M. See a summary of the company’s cash flow.
| Ratios | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.41 | 1.89 | 6.89 | 6.43 | 0.51 |
| Quick Ratio | 1.41 | 1.89 | 6.89 | 6.43 | 0.51 |
| Cash Ratio | 1.37 | 0.45 | 2.33 | 2.12 | 0.35 |
| Solvency Ratio | -0.50 | -1.12 | -1.10 | -2.17 | -0.62 |
| Operating Cash Flow Ratio | -1.52 | -2.91 | -2.04 | -1.22 | -1.31 |
| Short-Term Operating Cash Flow Coverage | -1.85 | 0.00 | -55.64 | -7.58 | -7.72 |
| Net Current Asset Value | $ -23.89M | $ -7.07M | $ 23.61M | $ 41.99M | $ -61.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.02 | 0.72 | 0.45 | 0.33 | 1.47 |
| Debt-to-Equity Ratio | -11.16 | -2.96 | 1.08 | 0.61 | -0.95 |
| Debt-to-Capital Ratio | 1.10 | 1.51 | 0.52 | 0.38 | -19.43 |
| Long-Term Debt-to-Capital Ratio | 1.15 | 1.51 | 0.50 | 0.33 | -2.44 |
| Financial Leverage Ratio | -10.93 | -4.10 | 2.39 | 1.82 | -0.65 |
| Debt Service Coverage Ratio | -1.29 | 0.00 | -14.95 | -10.98 | -1.66 |
| Interest Coverage Ratio | -7.41 | 0.00 | -12.87 | -4.42 | -2.13 |
| Debt to Market Cap | 1.31 | 0.74 | 2.80 | 0.42 | 0.12 |
| Interest Debt Per Share | 2.44 | 1.46 | 2.65 | 3.30 | 2.63 |
| Net Debt to EBITDA | -0.99 | -0.37 | -0.23 | -0.04 | -0.93 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.98% | 101.62% | 100.68% | 100.78% | 101.45% |
| EBT Per EBIT | 131.23% | 79.54% | 145.26% | 370.29% | 159.57% |
| Return on Assets (ROA) | -55.55% | -146.13% | -66.49% | -100.06% | -158.59% |
| Return on Equity (ROE) | 607.06% | 599.27% | -158.70% | -182.27% | 102.86% |
| Return on Capital Employed (ROCE) | -69.27% | -372.56% | -52.59% | -31.23% | 360.72% |
| Return on Invested Capital (ROIC) | -45.10% | -372.56% | -52.29% | -30.42% | 1741.25% |
| Return on Tangible Assets | -99.70% | -146.13% | -68.24% | -103.96% | -158.59% |
| Earnings Yield | -71.05% | -150.27% | -432.28% | -142.98% | -14.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.01 | 0.35 | 0.65 | 2.40 | 0.20 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -360.69 | -1042.02 | -562.51 | -152.31 | -1849.94 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 360.69 | 1042.02 | 562.51 | 152.31 | 1849.94 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.36 | -3.03 | -1.51 | -1.45 | -2.27 |
| Free Cash Flow Per Share | -1.36 | -3.04 | -1.51 | -1.46 | -2.27 |
| Dividend Paid and CapEx Coverage Ratio | -13385.00 | -3025.38 | -297.95 | -259.70 | -4957.09 |
| Capital Expenditure Coverage Ratio | -13385.00 | -3025.38 | -297.95 | -259.70 | -4957.09 |
| Operating Cash Flow Coverage Ratio | -0.59 | -2.07 | -0.61 | -0.52 | -1.13 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -76.78% | -154.07% | -180.32% | -24.83% | -15.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.40 | -0.67 | -0.23 | -0.70 | -6.85 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -8.54 | -3.99 | 0.37 | 1.27 | -7.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.30 | -0.65 | -0.55 | -4.03 | -6.53 |
| Price-to-Operating Cash Flow Ratio | -1.30 | -0.65 | -0.56 | -4.04 | -6.53 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.04 | 0.00 | 0.01 | -0.02 |
| Enterprise Value Multiple | -2.59 | -1.11 | -0.48 | -0.81 | -10.83 |
| Enterprise Value | 56.28M | 38.42M | 19.29M | 67.02M | 389.82M |
| EV to EBITDA | -2.59 | -1.11 | -0.48 | -0.81 | -10.83 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.10 | -0.98 | -1.04 | -4.21 | -7.15 |
| EV to Operating Cash Flow | -2.10 | -0.98 | -1.04 | -4.23 | -7.15 |
| Tangible Book Value Per Share | -1.21 | -0.49 | 2.15 | 4.30 | -2.11 |
| Shareholders’ Equity Per Share | -0.21 | -0.49 | 2.29 | 4.61 | -2.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.26 | -2.96 | -3.63 | -8.41 | -2.17 |
| Tax Burden | 1.01 | 1.02 | 1.01 | 1.01 | 1.01 |
| Interest Burden | 1.11 | 1.04 | 1.06 | 1.07 | 1.42 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.08 | 1.02 | 0.42 | 0.17 | 1.05 |
Currency in USD
